FDA Clones Misguided Regulatory Policy

The Food and Drug Administration (FDA) has just launched two salvos in federal agencies' war against biotechnology by attacking various manifestations of the biological process called cloning, in which a mature cell--from the skin, for example--from the animal (or human) to be copied is inserted into an egg whose nucleus has been removed. The resulting embryo is then implanted into a surrogate mother that carries the fetus to term. In response to public claims by two groups that they are attem

Written byHenry Miller
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

In response to public claims by two groups that they are attempting to produce a human baby using the cloning technology used to create Dolly the sheep and other animals, a senior FDA official in March threatened to shut down any such attempts. Dr. Kathryn Zoon, director of the Center for Biologics Evaluation and Research, testified that "FDA views the use of cloning technology to clone a human being as a cause for public health concern," and assured members of a subcommittee of the House Committee on Energy and Commerce that "FDA would not permit any such investigation to proceed."

More recently, the agency told companies that clone livestock that neither the duplicated animals nor their offspring may enter the food chain. Officials at the FDA's Center for Veterinary Medicine have said they consider these genetically identical cattle and pigs--analogous to Dolly, the first cloned mammal--to be "experimental," and therefore ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies